Stocktoria
Solventum Corp SOLV
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2024-03-26
Solventum Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $8.3B | $8.3B | $8.2B |
| Gross profit | $4.5B | $4.6B | $4.7B |
| R&D expense | $739.0M | $775.0M | $758.0M |
| SG&A expense | $3.1B | $2.8B | $2.3B |
| Operating income | $2.2B | $1.0B | $1.7B |
| Income tax | $157.0M | $127.0M | $321.0M |
| Net income | $1.6B | $479.0M | $1.3B |
| EPS (diluted) | $8.88 | $2.76 | $7.79 |
| Operating cash flow | $369.0M | $1.2B | $1.9B |
| Free cash flow | -$10.0M | $805.0M | $1.6B |
| Cash & equivalents | $878.0M | $762.0M | $194.0M |
| Inventory | $1.1B | $965.0M | $857.0M |
| Total assets | $14.3B | $14.5B | $13.9B |
| Total liabilities | $9.2B | $11.5B | $2.3B |
| Shareholders' equity | $5.0B | $3.0B | $11.7B |
Source: SEC EDGAR filings · CIK 0001964738 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.